Is Indegene (INDGN) overvalued or fairly valued?

MarketChacha shows Indegene's valuation in context — a forward P/E of about 18.5, a price-to-book of about 3.8 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Indegene's revenue?

Indegene reported revenue of ₹1,221 Cr for FY2026, with net profit of ₹212 Cr, per official filings.

What is the share price of Indegene (INDGN)?

Indegene last traded at ₹493.35 (-3.1% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Indegene

INDGN · NSE · Healthcare/Tech · India

₹493.35-3.1%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 10:00 AM

Snapshot

TickerINDGN

ExchangeNSE

SectorHealthcare/Tech

IndustryHealth Information Services

CountryIndia

Employees4,687

HeadquartersBengaluru, India

Market cap₹11,866 Cr

P/B3.8

Volume1.02L

Websitewww.indegene.com

Filings tracked0

About Indegene

Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, and internationally. It operates through three segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation & Others. The company develops biotech and medical device for biopharmaceutical, emerging biotech, and medical device companies. It also offers enterprise commercial, medical, and clinical solutions; and omnichannel activation solutions. In addition, the company operates NEXT technology platforms. Further, it provides analytics, technology, commercial, medical, regulatory, and safety services to life science and healthcare organizations. Indegene Limited was incorporated in 1998 and is based in Bengaluru, India.

Profile as reported by Yahoo Finance.

Who owns it

Promoters55.7%
Institutions20.7%
Public & other23.7%

42 institutional holders

As reported by Yahoo Finance. Promoter pledge is not included here — that comes from exchange shareholding filings.

What's expected next

Next fiscal year

Rev ₹4,837 Cr · EPS 26.63

Est. earnings growth +26.1%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

₹414.0052-wk range₹596.80

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: BSE (official results filing)

Quarterly · last 2

Market cap

₹11,866 Cr

Day change

-3.1%

Fwd P/E

18.5

P/B

3.8

Div yield

0.44%

Beta

0.73

Revenue (FY2026)

₹1,221 Cr

Net margin

17.4%

EPS (FY2026)

8.83

Net profit (FY2026)

₹212 Cr

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about INDGN

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin
FY2026	₹1,221 Cr	₹212 Cr	8.83	17.4%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	₹368 Cr	₹72 Cr	3.00	19.6%
2025Q4	₹290 Cr	₹35 Cr	1.45	12.0%

Figures as reported, in ₹ (crore). Source: BSE (official results filing).

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.